Holders over time
- ACCV
- TMO
| Quarter | ACCV | TMO |
|---|---|---|
| Q4 2020 | none listed holders, n.a. | 33 holders, $39.2bn |
| Q1 2021 | none listed holders, n.a. | 35 holders, $36.5bn |
| Q2 2021 | none listed holders, n.a. | 33 holders, $38.3bn |
| Q3 2021 | none listed holders, n.a. | 32 holders, $42.6bn |
| Q4 2021 | none listed holders, n.a. | 38 holders, $50.1bn |
| Q1 2022 | none listed holders, n.a. | 32 holders, $43.2bn |
| Q2 2022 | none listed holders, n.a. | 33 holders, $38.9bn |
| Q3 2022 | none listed holders, n.a. | 26 holders, $34.3bn |
| Q4 2022 | none listed holders, n.a. | 29 holders, $37.0bn |
| Q1 2023 | none listed holders, n.a. | 35 holders, $37.1bn |
| Q2 2023 | none listed holders, n.a. | 39 holders, $33.5bn |
| Q3 2023 | none listed holders, n.a. | 39 holders, $32.6bn |
| Q4 2023 | none listed holders, n.a. | 41 holders, $32.7bn |
| Q1 2024 | none listed holders, n.a. | 30 holders, $34.1bn |
| Q2 2024 | none listed holders, n.a. | 38 holders, $30.6bn |
| Q3 2024 | none listed holders, n.a. | 30 holders, $33.8bn |
| Q4 2024 | none listed holders, n.a. | 36 holders, $27.6bn |
| Q1 2025 | none listed holders, n.a. | 31 holders, $24.2bn |
| Q2 2025 | none listed holders, n.a. | 39 holders, $18.8bn |
| Q3 2025 | none listed holders, n.a. | 32 holders, $21.9bn |
| Q4 2025 | none listed holders, n.a. | 32 holders, $29.9bn |
| Q1 2026 | none listed holders, n.a. | 34 holders, $24.4bn |
| Q2 2026 | none listed holders, n.a. | 36 holders, $26.4bn |
| Q3 2026 | 7 holders, $38m | 35 holders, $40.3bn |
Accelevation Holdings Corp
- Holders
- 0
- Reported value
- $0
- Buyers
- n.a.
- Sellers
- n.a.
No cross-section for this quarter.
Thermo Fisher Scientific Inc
- Holders
- 32
- Reported value
- $29.9bn
- Buyers
- 27
- Sellers
- 20
Breadth +7 among 92 comparable managers.
Who holds both, Q4 2025
Both (0)
No tracked manager lists every one of them.
Only ACCV (0)
None.
Only TMO (32)
AllianceBernstein LP, Arrowstreet Capital LP, Artisan Partners LP, Baillie Gifford & Co, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Dodge & Cox, Farallon Capital Management LLC, Fidelity (FMR LLC), GAMCO Investors Inc, Glenview Capital Management LLC, Harris Associates LP, Holocene Advisors LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Point72 Asset Management LP, Polen Capital Management LLC, Rokos Capital Management LLP, and 7 more
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.